Pharmafile Logo
Pharmafocus logo
Advanced Search

amyotrophic lateral sclerosis

Showing 9 posts of 9 posts found.

brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631

FDA decision on Neurizon’s ALS therapy delayed until October

August 18, 2025
Medical Communications Coya Therapeutics, Neurizon, Neurology, US Food and Drug Administration, amyotrophic lateral sclerosis

Neurizon Therapeutics has announced that the US Food and Drug Administration (FDA) will delay its decision on the company’s Clinical …

News

PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit

August 7, 2025
Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases

French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …

News

Neurizon confirms positive results for prospective ALS treatment

June 23, 2025
Research and Development Neurizon Therapeutics, Neurology, amyotrophic lateral sclerosis, blood-brain barrier, clinical data, neurodegenerative diseases

Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain …

News
hsm_mobile_clinical_trial_istock-872676342

Corcept reports survival benefit in ALS trial of dazucorilant despite missing primary endpoint

June 9, 2025
Research and Development Corcept Therapeutics, European Network to Cure ALS (ENCALS), Neurology, amyotrophic lateral sclerosis, clinical trial

Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients with amyotrophic lateral sclerosis (ALS), …

News
trials

Broken String Biosciences and the Francis Crick Institute collaborate on ALS research

May 7, 2024
Research and Development Broken String Biosciences, Francis Crick Institute, Neurology, amyotrophic lateral sclerosis, genomics

Genomics company Broken String Biosciences and biomedical discovery institute Francis Crick have announced a research collaboration, focusing on amyotrophic lateral …

News
biohaven_enrolls_first_patient_in-97b6e9e792e571e7c1572873932fc7c0

FDA knocks back Biohaven’s ALS drug over manufacturing concerns

July 22, 2019
Sales and Marketing Biohaven, FDA, Nurtec, amyotrophic lateral sclerosis, pharma

Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, …

News
shutterstock_159488225

Astellas and Cytokinetics’ reldesemtiv falls short at Phase 2 in ALS

May 7, 2019
Manufacturing and Production, Sales and Marketing Astellas, als, amyotrophic lateral sclerosis, cytokinetics, pharma

Cytokinetics has announced at the American Academy of Neurology (AAN) that its fast skeletal muscle troponin activator (FSTA) reldesemtiv fell …

News
shutterstock_138095450

Aquinnah Pharmaceuticals receives $3.4 million grant to advance ALS therapies

June 21, 2018
Research and Development, Sales and Marketing Aquinnah Pharmaceuticals, als, amyotrophic lateral sclerosis, pharma

Aquinnah Pharmaceuticals has announced that it has been awarded a $3.4 million grant from the National Institute of Neurological Disorders …

News

Biogen Idec buys neurodegenerative disease rights

December 21, 2010
Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases

Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026